Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis

By sjmartinez • July 16, 2024

Paik JJ, Vencovský J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, Mudd PN Jr, Aggarwal R. Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2024 Jul 15. doi: 10.55563/clinexprheumatol/eeglsa. Epub ahead of print. PMID: 39008325.

Tags: Publications, Rheumatology

Differences Among Veterans With Chronic Overlapping Pain Conditions and Other Chronic Pain: Baseline Results From the LAMP Pain Management Trial

Adamowicz JL, Grant A, Calvert C, Elchert D, Hadlandsmyth K, Driscoll MA, Taylor SL, Allen K, Taylor BC, Burgess DJ. Differences Among Veterans With Chronic[...]

Risk of Cutaneous T-cell Lymphoma in Patients with Autoimmune Diseases

Brumbaugh B, Westmeijer M, Thompson B, Holt A, Ebriani J, Sheng-Kai Ma K, Chen ST. Risk of Cutaneous T-cell Lymphoma in Patients with Autoimmune Diseases.[...]

SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis

Herrmann K, Walz J, MacLennan S, Briganti A, Cornford P, Czernin J, Eiber M, Fanti S, Fendler WP, Fizazi K, Gafita A, Gillessen S, Goffin[...]